A Pilot Study of Circulating Tumor DNA Adaptive Risk Maintenance Approach for Bladder Cancer (CARMA)

NCT06050954 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Change in standard of care.

Conditions

Metastatic Urothelial Carcinoma

Interventions

DRUG: Pembrolizumab (200mg)
DRUG: Pembrolizumab (400mg)
DIAGNOSTIC_TEST: Monitoring

Sponsor

Fox Chase Cancer Center